Veradermics (NYSE: MANE) announced the pricing of its public offering of 3,843,790 shares of common stock at $100.00 per share. The biopharmaceutical company expects gross proceeds of approximately $384.4 million before deducting underwriting discounts and other expenses.

The offering is expected to close on May 1, 2026, subject to customary closing conditions. Veradermics has granted underwriters a 30-day option to purchase up to an additional 576,568 shares at the same price, less underwriting discounts and commissions.

The company also entered into a securities purchase agreement to sell 300,000 pre-funded warrants at $99.99999 per share to entities affiliated with Suvretta Capital in a private placement. The private placement is expected to generate approximately $30.0 million in gross proceeds before fees and expenses.

Jefferies, Leerink Partners, Citigroup, and Cantor are serving as joint bookrunning managers for the offering. LifeSci Capital is acting as passive bookrunner, while Needham & Company is the lead manager. These firms are also acting as placement agents for the private placement.

Veradermics develops therapeutics for pattern hair loss. The company's lead program, VDPHL01, is an oral, extended-release formulation of minoxidil designed as a non-hormonal treatment for men and women with pattern hair loss.

The securities in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States except pursuant to an effective registration statement or applicable exemption.